Novabay Pharmaceuticals Inc (AMEX: NBY) closed the day trading at $0.10 down -3.35% from the previous closing price of $0.10. In other words, the price has decreased by -$0.0035 from its previous closing price. On the day, 1866846 shares were traded.
Ratios:
For a better understanding of NBY, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.00 and its Current Ratio is at 1.67. In the meantime, Its Debt-to-Equity ratio is 0.83 whereas as Long-Term Debt/Eq ratio is at 0.34.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Ladenburg Thalmann on September 18, 2019, initiated with a Buy rating and assigned the stock a target price of $1.10.
On July 06, 2018, H.C. Wainwright reiterated its Buy ratingand also kept the price unchanged to $4.
Laidlaw reiterated its Buy rating for the stock on November 15, 2017, while the target price for the stock was revised from $10 to $8.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NBY now has a Market Capitalization of 3.04M and an Enterprise Value of 4.60M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.21 while its Price-to-Book (P/B) ratio in mrq is 0.83. Its current Enterprise Value per Revenue stands at 0.31 whereas that against EBITDA is -0.96.
Stock Price History:
Over the past 52 weeks, NBY has reached a high of $1.95, while it has fallen to a 52-week low of $0.10. The 50-Day Moving Average of the stock is 0.1408, while the 200-Day Moving Average is calculated to be 0.3817.
Shares Statistics:
Over the past 3-months, NBY traded about 3.64M shares per day on average, while over the past 10 days, NBY traded about 3.28M shares per day. A total of 30.10M shares are outstanding, with a floating share count of 29.36M. Insiders hold about 2.44% of the company’s shares, while institutions hold 3.95% stake in the company. Shares short for NBY as of Mar 15, 2024 were 116.07k with a Short Ratio of 0.03, compared to 302.42k on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.39% and a Short% of Float of 0.39%.
Earnings Estimates
Current recommendations for the stock of the company come from 1 analysts. On average, analysts expect EPS of -$0.25 for the current quarter, with a high estimate of -$0.25 and a low estimate of -$0.25, while EPS last year was -$0.85. The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.14 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.41 and -$0.41 for the fiscal current year, implying an average EPS of -$0.41. EPS for the following year is $0.07, with 1 analysts recommending between $0.07 and $0.07.
Revenue Estimates
1 analysts predict $3.56M in revenue for the current quarter. It ranges from a high estimate of $3.56M to a low estimate of $3.56M. As of the current estimate, Novabay Pharmaceuticals Inc’s year-ago sales were $3.2M, an estimated increase of 11.20% from the year-ago figure.
A total of 1 analysts have provided revenue estimates for NBY’s current fiscal year. The highest revenue estimate was $16.1M, while the lowest revenue estimate was $16.1M, resulting in an average revenue estimate of $16.1M. In the same quarter a year ago, actual revenue was $14.73M, up 9.30% from the average estimate. Based on 1 analysts’ estimates, the company’s revenue will be $21.57M in the next fiscal year. The high estimate is $21.57M and the low estimate is $21.57M. The average revenue growth estimate for next year is up 34.00% from the average revenue estimate for this year.
